Cantor Fitzgerald Comments on Nabriva Therapeutics AG’s FY2017 Earnings (NBRV)
Nabriva Therapeutics AG (NASDAQ:NBRV) – Equities researchers at Cantor Fitzgerald increased their FY2017 earnings per share (EPS) estimates for Nabriva Therapeutics AG in a research note issued to investors on Tuesday. Cantor Fitzgerald analyst L. Chen now forecasts that the biotechnology company will earn ($2.15) per share for the year, up from their previous forecast of ($2.18). Cantor Fitzgerald has a “Buy” rating and a $16.00 price target on the stock.
A number of other equities research analysts have also issued reports on NBRV. Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Thursday. HC Wainwright restated a “buy” rating on shares of Nabriva Therapeutics AG in a report on Friday, May 12th. ValuEngine lowered shares of Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Finally, Wedbush restated an “outperform” rating and set a $13.00 price target on shares of Nabriva Therapeutics AG in a report on Monday, May 15th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $15.43.
Shares of Nabriva Therapeutics AG (NASDAQ NBRV) opened at 9.78 on Thursday. The company’s 50-day moving average is $10.41 and its 200-day moving average is $10.34. The firm’s market cap is $26.61 million. Nabriva Therapeutics AG has a 12 month low of $3.52 and a 12 month high of $12.75.
Nabriva Therapeutics AG (NASDAQ:NBRV) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($5.83) by $5.29. The firm had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.34 million.
In related news, major shareholder Hbm Healthcare Investments (Ca sold 8,558 shares of the business’s stock in a transaction that occurred on Thursday, June 29th. The shares were sold at an average price of $10.96, for a total transaction of $93,795.68. Following the transaction, the insider now directly owns 2,591,396 shares of the company’s stock, valued at $28,401,700.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director George Harrison Talbot sold 325 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $100.56, for a total transaction of $32,682.00. Following the transaction, the director now directly owns 3,854 shares in the company, valued at $387,558.24. The disclosure for this sale can be found here. Insiders have sold 242,708 shares of company stock worth $2,646,784 over the last ninety days.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC bought a new position in shares of Nabriva Therapeutics AG during the fourth quarter worth approximately $103,000. Almanack Investment Partners LLC. bought a new position in shares of Nabriva Therapeutics AG during the first quarter worth approximately $1,870,000. Nationwide Fund Advisors bought a new position in shares of Nabriva Therapeutics AG during the first quarter worth approximately $2,074,000. Finally, Wellington Management Group LLP increased its position in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares during the last quarter. 56.65% of the stock is currently owned by hedge funds and other institutional investors.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with Analyst Ratings Network's FREE daily email newsletter.